Compare Aventis Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SUN PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SUN PHARMA SANOFI INDIA/
SUN PHARMA
 
P/E (TTM) x 34.4 28.1 122.3% View Chart
P/BV x 6.0 2.4 248.2% View Chart
Dividend Yield % 1.4 0.7 219.8%  

Financials

 SANOFI INDIA   SUN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
SUN PHARMA
Mar-19
SANOFI INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs6,840679 1,007.7%   
Low Rs4,630375 1,233.4%   
Sales per share (Unadj.) Rs1,203.1121.1 993.1%  
Earnings per share (Unadj.) Rs165.313.4 1,235.5%  
Cash flow per share (Unadj.) Rs209.920.7 1,014.6%  
Dividends per share (Unadj.) Rs84.002.75 3,054.5%  
Dividend yield (eoy) %1.50.5 280.7%  
Book value per share (Unadj.) Rs963.6172.6 558.3%  
Shares outstanding (eoy) m23.032,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.84.4 109.6%   
Avg P/E ratio x34.739.4 88.1%  
P/CF ratio (eoy) x27.325.5 107.2%  
Price / Book Value ratio x6.03.1 194.9%  
Dividend payout %50.820.6 247.2%   
Avg Mkt Cap Rs m132,0781,264,650 10.4%   
No. of employees `0003.317.5 18.9%   
Total wages/salary Rs m4,06859,671 6.8%   
Avg. sales/employee Rs Th8,393.816,608.1 50.5%   
Avg. wages/employee Rs Th1,232.43,409.6 36.1%   
Avg. net profit/employee Rs Th1,153.01,833.8 62.9%   
INCOME DATA
Net Sales Rs m27,708290,659 9.5%  
Other income Rs m89710,255 8.7%   
Total revenues Rs m28,605300,914 9.5%   
Gross profit Rs m6,23563,076 9.9%  
Depreciation Rs m1,02717,533 5.9%   
Interest Rs m75,553 0.1%   
Profit before tax Rs m6,09850,246 12.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m2,2926,009 38.1%   
Profit after tax Rs m3,80632,093 11.9%  
Gross profit margin %22.521.7 103.7%  
Effective tax rate %37.612.0 314.3%   
Net profit margin %13.711.0 124.4%  
BALANCE SHEET DATA
Current assets Rs m15,922310,692 5.1%   
Current liabilities Rs m6,235173,396 3.6%   
Net working cap to sales %35.047.2 74.0%  
Current ratio x2.61.8 142.5%  
Inventory Days Days6499 64.3%  
Debtors Days Days21112 18.7%  
Net fixed assets Rs m7,539232,477 3.2%   
Share capital Rs m2302,399 9.6%   
"Free" reserves Rs m21,962411,691 5.3%   
Net worth Rs m22,192414,091 5.4%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m29,839646,938 4.6%  
Interest coverage x872.110.0 8,678.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.4 206.7%   
Return on assets %12.85.8 219.6%  
Return on equity %17.27.8 221.3%  
Return on capital %27.510.2 270.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58766,025 11.5%   
Fx outflow Rs m7,14538,610 18.5%   
Net fx Rs m44227,415 1.6%   
CASH FLOW
From Operations Rs m3,73921,965 17.0%  
From Investments Rs m-731-6,813 10.7%  
From Financial Activity Rs m-1,972-27,305 7.2%  
Net Cashflow Rs m1,036-8,442 -12.3%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 5.1 280.7%  
FIIs % 14.6 23.0 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   15,184 133,026 11.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 18, 2019 12:23 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS